Verve Therapeutics, Inc. - Common Stock, par value $0.001 per share (VERV)

Historical Holders from Q2 2021 to Q3 2025

Type / Class
Equity / Common Stock, par value $0.001 per share
Symbol
VERV
Shares outstanding
89,600,000
Price per share
$11.23
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares as of 30 Sep 2025
115,958
Total reported value
$1,373,904
% of total 13F portfolios
0%
Share change
-72,274,637
Value change
-$811,684,524
Avg buy value change
+0%
Avg sell value change
-0%
Number of holders
6
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Verve Therapeutics, Inc. - Common Stock, par value $0.001 per share (VERV) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Pentwater Capital Management LP 7.5% $74,793,600 6,720,000 Pentwater Capital Management LP 30 Jun 2025
BlackRock, Inc. 7% $18,347,920 6,177,751 BlackRock, Inc. 31 Mar 2025
MILLENNIUM MANAGEMENT LLC 4.9% +6% $12,851,864 +$1,212,045 4,327,227 +10% Millennium Management LLC 22 Apr 2025
STATE STREET CORP 3.8% $9,610,169 3,235,747 STATE STREET CORPORATION 31 Dec 2024
As of 30 Sep 2025, Verve Therapeutics, Inc. - Common Stock, par value $0.001 per share (VERV) has 6 institutional shareholders filing 13F forms. They hold 115,958 shares. of 89,600,000 outstanding shares (0.13%) .

Institutional Holders of Verve Therapeutics, Inc. - Common Stock, par value $0.001 per share (VERV) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (% of par) Investors
2025 Q3 115,958 $1,373,904 -$811,684,524 1,123% 6
2025 Q2 72,945,134 $819,296,389 +$44,435,746 1,123% 172
2025 Q1 80,771,198 $369,084,738 +$7,858,739 457% 189
2024 Q4 78,638,659 $443,551,119 +$18,812,165 564% 162
2024 Q3 75,176,010 $363,867,519 -$7,273,425 484% 169
2024 Q2 76,100,300 $371,371,442 +$9,871,204 488% 161
2024 Q1 4,387,437 $58,179,765 -$559,758 1,328% 17
2023 Q4 111,999 $1,572,679 -$352,656 1,394% 3
2023 Q3 63,784,896 $845,806,729 +$19,484,294 1,326% 127
2023 Q2 61,735,739 $1,157,500,538 -$20,078,116 1,875% 115
2023 Q1 63,268,502 $911,647,523 +$3,330,765 1,442% 122
2022 Q4 62,621,631 $1,211,733,927 +$9,152,658 1,935% 117
2022 Q3 60,384,536 $2,071,970,600 +$500,503,050 3,435% 119
2022 Q2 45,361,340 $692,609,569 -$28,199,899 1,528.01% 92
2022 Q1 46,636,122 $1,063,920,978 +$20,036,438 2,281.99% 91
2021 Q4 45,131,613 $1,661,911,200 +$124,859,224 3,687% 87
2021 Q3 38,717,676 $1,813,712,011 +$24,134,055 4,700% 72
2021 Q2 37,677,848 $2,254,530,000 +$2,254,530,073 6,025% 69